Related Experiment Videos
Anti-HBs kinetics after HBV vaccination in neonates
R Vranckx1, A Alisjahbana, W Ngantung
1Institute of Hygiene and Epidemiology, Brussels, Belgium.
Clinical and Diagnostic Virology
|October 1, 1994
Summary
Hepatitis B vaccine kinetics in newborns are similar to adults, suggesting personalized booster schedules based on individual antibody titers can optimize long-term protection against HBV infection.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- Hepatitis B virus (HBV) infection poses a significant risk in endemic areas.
- Recombinant DNA HBV vaccines are crucial for preventing perinatal transmission.
Purpose of the Study:
- To evaluate anti-HBs antibody kinetics in newborns vaccinated with a recombinant DNA HBV vaccine.
- To compare neonatal anti-HBs kinetics with adult data for booster vaccination needs.
- To estimate the optimal timing for booster vaccinations in neonates.
Main Methods:
- 148 neonates received a recombinant DNA HBV vaccine and were followed for 62 months.
- Neonates were categorized into 'exposed' and 'non-exposed' groups based on maternal HBV surface antigen status.
- Anti-HBs antibody titers were measured over time to assess vaccine effectiveness and decay.
Main Results:
- Neonatal anti-HBs titers were comparable to adult levels at 60 months post-vaccination.
- Individual titer calculations predicted that 8.3% of neonates require a booster within 14 months, 26.7% within 50 months, and 65% after 50 months.
- A minimum anti-HBs level of 10 IU/L was used as the threshold for protection.
Conclusions:
- Anti-HBs kinetics are similar in neonates and adults, supporting comparable vaccination strategies.
- Individual titer monitoring post-booster vaccination is an effective method for determining personalized booster intervals.
- This approach offers a cost-effective strategy for maintaining long-term protection against HBV in vaccinated neonates.